Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial

Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial


Eli Lilly & Co. said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial.



from Biotech News